These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33569642)

  • 1. Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
    Todenhöfer T; Maas M; Ketz M; Kossack N; Colling C; Qvick B; Stenzl A
    World J Urol; 2021 Aug; 39(8):2953-2960. PubMed ID: 33569642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
    Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
    Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
    Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
    Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
    Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
    Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
    Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
    BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
    Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
    Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
    Gkritsios P; Hatzimouratidis K; Kazantzidis S; Dimitriadis G; Ioannidis E; Katsikas V
    Int Urol Nephrol; 2014 May; 46(5):927-33. PubMed ID: 24249423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
    Geavlete B; Multescu R; Georgescu D; Geavlete P
    J Endourol; 2009 Jun; 23(6):977-81. PubMed ID: 19473068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HELENA study: Hexvix
    Gierth M; Breyer J; Zeman F; Fritsche HM; Cordes J; Karl A; Zaak D; Stenzl A; von Schmeling IK; Sommerhuber A; Zierer T; Burger M; Mayr R
    World J Urol; 2021 Oct; 39(10):3799-3805. PubMed ID: 34002265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
    Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
    Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
    Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
    Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAL fluorescence cystoscopy and TURB one year of Romanian experience.
    Geavlete B; Mulţescu R; Georgescu D; Jecu M; Geavlete P
    J Med Life; 2009; 2(2):185-90. PubMed ID: 20108538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could we safely omit a Repeat Transurethral Resection of the Bladder (re-TURB) after Hexaminolevulinate Photodynamic Diagnostics (PDD)-TURB?
    Lorusso V; Doisy L; Granata AM; Gregori A; Manfredi C; Spirito L; Sciorio C; Ciancimino LGM; Molteni S; Morelli M; Cirillo L; Napolitano L; Walz J; Pignot G
    Arch Ital Urol Androl; 2022 Dec; 94(4):424-427. PubMed ID: 36576467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
    World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): Cost impact of transurethral resection of bladder tumor in Japan.
    Fukuhara H; Hagiwara Y; Oba K; Inoue K
    Photodiagnosis Photodyn Ther; 2023 Dec; 44():103758. PubMed ID: 37604217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Real-life experience': recurrence rate at 3 years with Hexvix
    Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
    World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.